Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Nifty500 Multicap India Manufacturing 50:30:20
Nifty500 Multicap India Manufacturing 50:30:20 Performance
Day's Range
Low
₹16,100.10
High
₹16,292.75
52 Week Range
Low
₹14,148.20
High
₹16,649.05
| Previous Close | ₹16,261.55 |
|---|---|
| Day's Range | ₹16,100.10 - ₹16,292.75 |
| Open | ₹16,287.25 |
| 52 Week Range | ₹14,148.20 - ₹16,649.05 |
| Volume | 44,25,51,840 |
Nifty500 Multicap India Manufacturing 50:30:20 Companies
| Company Name | LTP (₹) | Change (₹) | Sector |
|---|---|---|---|
| Amara Raja Energy & Mobility Ltd. | 823.95 |  -11.30 (-1.35%) |
Automobile & Ancillaries |
| Atul Ltd. | 7100.00 |  130.00 (1.87%) |
Chemicals |
| Bharat Electronics Ltd. | 423.65 | -5.20 (-1.21%) |
Capital Goods |
| Chambal Fertilisers and Chemicals Ltd. | 449.90 | 25.30 (5.96%) |
Chemicals |
| Exide Industries Ltd. | 349.05 | -0.65 (-0.19%) |
Automobile & Ancillaries |
| Cipla Ltd. | 1432.10 | -4.60 (-0.32%) |
Healthcare |
| Bharat Heavy Electricals Ltd. | 398.30 | -14.85 (-3.59%) |
Capital Goods |
| Hindustan Petroleum Corporation Ltd. | 366.40 | -11.15 (-2.95%) |
Crude Oil |
| Dr. Reddy's Laboratories Ltd. | 1336.70 | 33.10 (2.54%) |
Healthcare |
| Hero MotoCorp Ltd. | 5064.50 | -12.50 (-0.25%) |
Automobile & Ancillaries |
| Index Name | Market Value | 52W High | 52W Low |
|---|---|---|---|
| Nifty 50 | 23643.5 | 26373.20 | 22182.55 |
| Nifty IT | 27716.9 | 40301.40 | 27078.00 |
| Nifty Next 50 | 69280.25 | 72037.60 | 59896.10 |
| NIFTY50 USD Index | 8543.55 | 10443.40 | 8132.40 |
| Nifty Bank | 53710.35 | 61764.85 | 49954.85 |
| NIFTY Midcap 100 | 60567.15 | 62113.85 | 52032.85 |
| Nifty 500 | 22531.15 | 24144.20 | 20385.65 |
| Nifty Midcap 50 | 17273.15 | 17686.30 | 14804.55 |
| Nifty 100 | 24572.15 | 26975.15 | 22720.45 |
| Nifty FMCG | 51051.35 | 58485.05 | 45334.15 |
Latest News
Gland Pharma informs about newspaper advertisement
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, Gland Pharma has informed that it enclosed copies of the newspaper advertisement pertaining to Audited Financial Results of the Company for the financial year ended March 31, 2026. The advertisements were published in English and Telugu newspapers.
The above information is a part of company’s filings submitted to BSE.
Aurobindo Pharma informs about updates
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that: CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, announced that the Central Drugs Standard Control Organization (CDSCO) has granted Marketing Authorisation under Form CT 23 for Bevqolva®, a bevacizumab biosimilar indicated for metastatic carcinoma of the colon or rectum. The authorisation permits manufacture at CuraTeQ’s facility in Hyderabad and marketing of Bevqolva® in 100 mg/4mL and 400 mg/16 mL vial presentations.
The above information is a part of company’s filings submitted to BSE.
Amber Enterprises India informs about investor presentation
Pursuant to the Regulation 30 and other relevant provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, Amber Enterprises India has informed that it enclosed Investor Presentation on the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and financial year ended 31st March 2026. This information is also being hosted on the Company’s website, at https://www.ir.ambergroupindia.com/investor-information/investor-presentations/.
The above information is a part of company’s filings submitted to BSE.
Amber Enterprises India informs about outcome of board meeting
In continuation of its intimation dated 11th May 2026, Amber Enterprises India has informed that the Board of Directors of the Company, at its meeting held on Friday, 15th May 2026, has, considered and approved the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and financial year ended 31st March 2026. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, (‘SEBI (LODR) Regulations’), it has submitted the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and financial year ended 315 March 2026, along with the Auditor's Report issued by the Statutory Auditor of the Company, S.R. Batliboi & Co LLP. The aforesaid documents are enclosed. Further, pursuant to Regulation 33(3)(d) of the SEBI (LODR) Regulations, it has informed that the Statutory Auditors have issued a Modified Opinion on the Audited Consolidated Financial Results. In this regard, the Statement on Impact of Audit Qualifications (for Modified Opinion), in the prescribed format, is enclosed. An extract of the aforementioned Audited Financial Results (Standalone and Consolidated) will be published in newspapers in accordance with the requirements of the SEBI (LODR) Regulations. The meeting of the Board of Directors commenced at 12:30 pm IST and concluded at 11:55 pm IST. The Audited Financial Results of the Company for the quarter and financial year ended 31st March 2026, shall also be made available on the Company's website.
The above information is a part of company’s filings submitted to BSE.
Dr. Reddy’s Laboratories informs about press release
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The previous close of Ny500MUL50:30:20 index is ₹16139.55 as of 2026-05-15.
The total volume of Ny500MUL50:30:20 index is 440570215.00 as of 2026-05-15.
The percentage change in value of Ny500MUL50:30:20 index is -0.75% as of 2026-05-15.
The absolute increase in Ny500MUL50:30:20 index value since the previous trading day is ₹-122.0 as of 2026-05-15.
A stock reaching its 52-week high indicates it has attained its highest price point in the past year. This milestone may signal strong performance and positive investor sentiment. Please note that investments are subject to market risks.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
